Precautionary Health Behaviours as Potential Confounders in COVID-19 Vaccine Effectiveness Studies
Authors:
- Chloé Wyndham-ThomasCWChloé Wyndham-Thomas
- Leonie de MunterLMLeonie de Munter
- Konstantina ChatzikonstantinidouKCKonstantina Chatzikonstantinidou
- Charlotte MartinCMCharlotte Martin
- Gerrit Luit Ten KateGKGerrit Luit Ten Kate
- Nicolas PraetNPNicolas Praet
- Wilhelmine MeerausWMWilhelmine Meeraus
- Matthew D. RousculpMRMatthew D. Rousculp
- Kaatje BollaertsKBKaatje Bollaerts
Open Access
Abstract
Background/Objectives: Precautionary health behaviours (PHBs), such as hand-washing or self-isolation, are non-pharmaceutical interventions used to reduce SARS-CoV-2 transmission. We investigated the potential confounding by PHBs of COVID-19 vaccine effectiveness (VE) estimates in a subset of study participants enrolled in id.DRIVE. Methods: The id.DRIVE COVID-19 VE study (formerly COVIDRIVE) is a European multicentre test-negative case–control study estimating COVID-19 VE against hospitalisation due to laboratory-confirmed SARS-CoV-2 in patients with severe acute respiratory infection. All adults (≥18 y) prospectively enrolled between 16 November 2021 and 16 August 2023 at three sites were invited to complete a PHB survey capturing indicators of PHBs in the 3 months preceding admission. Fisher’s exact test with Bonferroni-adjusted threshold was used to measure the level of association between PHB indicators and both COVID-19 vaccine status and SARS-CoV-2 test result. VE estimates were generated with and without adjustment for PHBs. Results: PHBs were modified over time, with higher precautionary attitudes in the first COVID-19 vaccine booster season (2021–2022) compared to the second one (2022–2023). For the first booster season, PHBs were positively associated with exposures (vaccination status) and outcomes (case or control status). Adjusting for PHBs led to a 6 to 9 percentage-point increase in VE estimates. Conversely, no confounding by PHBs was observed in the second booster season. Conclusions: PHBs should be considered a possible confounder of COVID-19 VE studies. Further research is needed to define when PHBs should be integrated into VE models, as the level of confounding may differ according to the study population and the epidemiological context.Keywords
Funding Information
- id.DRIVE
- AstraZeneca
This publication has 28 references indexed in Scilit:
- Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: a retrospective surveillance studyThe Lancet Respiratory Medicine, 2024
- Factors associated with compliance with barrier gestures and social distancing measures in FranceJournal of Epidemiology and Population Health, 2024
- Protection against COVID-19 hospitalisation conferred by primary-series vaccination with AZD1222 in non-boosted individuals: first vaccine effectiveness results of the European COVIDRIVE study and meta-regression analysisThe Lancet Regional Health - Europe, 2023
- Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational studyThe Lancet Infectious Diseases, 2022
- Quantifying the RSV immunity debt following COVID-19: a public health matterThe Lancet Infectious Diseases, 2022
- Understanding the rebound of influenza in the post COVID-19 pandemic period holds important clues for epidemiology and controlInternational Journal of Infectious Diseases, 2022
- Time patterns of precautionary health behaviours during an easing phase of the COVID-19 pandemic in EuropeEuropean Journal of Ageing, 2021
- Non-pharmaceutical interventions during the COVID-19 pandemic: A reviewPhysics Reports, 2021
- Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communicationsThe Lancet Regional Health - Europe, 2021
- Seasonal influenza vaccine effectiveness estimates: Development of a parsimonious case test negative model using a causal approachVaccine, 2016